dexlansoprazole: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287	NDA AUTHORIZED GENERIC	A-S Medication Solutions	50090-5944-0	30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (50090-5944-0)	2022-01-01
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287	NDA AUTHORIZED GENERIC	A-S Medication Solutions	50090-5944-1	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (50090-5944-1)	2022-01-01
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287	NDA	Takeda Pharmaceuticals America, Inc.	64764-171-00	7 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-00)	2010-04-12
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287	NDA	Takeda Pharmaceuticals America, Inc.	64764-171-01	5 BLISTER PACK in 1 TRAY (64764-171-01) / 4 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK	2010-04-12
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This analysis details the key suppliers and critical raw materials involved in the manufacturing of dexlansoprazole, a proton pump inhibitor (PPI). The identification of these suppliers is crucial for assessing supply chain stability, potential risks, and competitive positioning for pharmaceutical companies. The dexlansoprazole market is characterized by established active pharmaceutical ingredient (API) manufacturers and a complex network of intermediate and excipient suppliers.

What is Dexlansoprazole and its Market Significance?

Dexlansoprazole is an orally administered proton pump inhibitor (PPI) used to treat conditions such as heartburn, erosive esophagitis, and gastroesophageal reflux disease (GERD). It functions by reducing the amount of acid produced in the stomach. The drug's unique dual-delayed release formulation allows for a sustained release of the active ingredient, providing prolonged acid suppression. This characteristic differentiates it from other PPIs and contributes to its sustained market presence.

The global market for PPIs, including dexlansoprazole, is substantial, driven by the high prevalence of acid-related gastrointestinal disorders worldwide. Factors such as aging populations, lifestyle changes contributing to poor dietary habits, and increasing awareness of GERD symptoms fuel demand. The competitive landscape includes both branded and generic versions of dexlansoprazole, necessitating efficient and cost-effective manufacturing processes for suppliers.

Who are the Primary API Manufacturers for Dexlansoprazole?

The production of dexlansoprazole API is concentrated among a select group of global pharmaceutical manufacturers. These companies possess the specialized chemical synthesis capabilities and regulatory compliance necessary for large-scale API production. Key players in this segment include:

Takeda Pharmaceutical Company Limited: As the originator of Dexilant (dexlansoprazole), Takeda is a primary manufacturer. Their focus is on maintaining quality and intellectual property protection for the branded product.
Major Generic API Manufacturers: Several large-scale generic API manufacturers globally produce dexlansoprazole. These include companies based in India and China, which are significant hubs for pharmaceutical ingredient manufacturing due to cost advantages and established infrastructure. Examples of such companies, often supplying to multiple finished dosage form manufacturers, include:
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Lupin Ltd.
- Cipla Ltd.
- Zydus Lifesciences Ltd. (formerly Cadila Healthcare)
- Aurobindo Pharma Ltd.
- Hospira (a Pfizer company) - while historically a significant player, their API manufacturing focus can shift.
- Teva Pharmaceutical Industries Ltd.

The selection of an API manufacturer by a finished dosage form producer depends on several factors, including cost, quality certifications (e.g., GMP compliance), regulatory history, production capacity, and supply chain reliability.

What are the Critical Raw Materials and Intermediate Suppliers?

The synthesis of dexlansoprazole involves a multi-step chemical process, relying on several key raw materials and intermediates. The quality and consistent availability of these components are paramount to ensuring the efficacy and safety of the final drug product.

Key Chemical Intermediates

The synthesis pathway for dexlansoprazole typically involves the preparation of benzimidazole derivatives and pyridine derivatives, which are then coupled. Critical intermediates include:

5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole: This is a direct precursor to dexlansoprazole. Its own synthesis requires specific precursor chemicals.
2-Chloromethyl-3,5-dimethyl-4-methoxypyridine hydrochloride: This pyridine derivative is a crucial building block.
2-(Mercaptomethyl)-5-methoxy-1H-benzimidazole or related sulfur-containing benzimidazole: This benzimidazole derivative is another essential precursor.

Suppliers of these advanced intermediates are often specialized chemical manufacturers with expertise in complex organic synthesis. These can include:

Advanced Intermediates Manufacturers: Companies that specialize in producing multi-step synthesized chemical compounds for the pharmaceutical industry. Many of the major API manufacturers may have in-house capabilities for these intermediates or work with trusted toll manufacturers.
Custom Synthesis Providers: Firms that offer bespoke synthesis services, creating specific chemical entities on demand for pharmaceutical clients.

Basic Raw Materials and Reagents

The synthesis of the above intermediates, and ultimately dexlansoprazole, requires a range of basic chemicals, solvents, and reagents. These are generally more commoditized but require strict quality control.

Solvents: Common solvents include methanol, ethanol, isopropanol, toluene, dichloromethane, and ethyl acetate. These are sourced from major industrial chemical suppliers.
Reagents: Acids (e.g., hydrochloric acid, sulfuric acid), bases (e.g., sodium hydroxide, potassium carbonate), oxidizing agents (e.g., m-chloroperoxybenzoic acid - MCPBA, or alternative oxidizers for the sulfoxide formation), reducing agents, and catalysts are essential.
Starting Materials: Simpler organic compounds that form the initial building blocks for the benzimidazole and pyridine rings.

Suppliers for these basic materials include:

Industrial Chemical Companies: Large-scale producers of bulk chemicals and solvents. Examples include BASF, Dow Chemical Company, and local regional suppliers.
Specialty Chemical Suppliers: Companies that offer high-purity reagents and analytical grade chemicals.

What are the Excipient Suppliers for Dexlansoprazole Formulations?

Dexlansoprazole is typically formulated into delayed-release capsules. The formulation requires various inactive ingredients, or excipients, that are critical for drug delivery, stability, and patient acceptance. These include:

Fillers/Diluents: Used to increase the bulk of the tablet or capsule.
- Microcrystalline Cellulose (MCC): Widely used for its binding and disintegrant properties.
- Lactose Monohydrate: Another common filler, though its use is sometimes limited due to lactose intolerance.
- Mannitol: Often used in orally disintegrating tablets but can also serve as a filler.
Binders: Hold the active ingredient and other excipients together to form granules.
- Hydroxypropyl Cellulose (HPC)
- Povidone (PVP)
Disintegrants: Help the tablet or capsule break apart in the digestive tract.
- Croscarmellose Sodium
- Sodium Starch Glycolate
Lubricants: Prevent sticking to manufacturing equipment.
- Magnesium Stearate
- Stearic Acid
Glidants: Improve powder flow.
- Colloidal Silicon Dioxide
Coating Agents: For the delayed-release functionality and capsule shell.
- Methacrylic Acid Copolymers (e.g., Eudragit® series): These are critical for the dual-delayed release mechanism, controlling pH-dependent drug release.
- Hypromellose Phthalate (HPMCP): Another pH-dependent polymer.
- Gelatin or Hypromellose (HPMC): For capsule shells.
- Titanium Dioxide: As an opacifier and white pigment.
- Iron Oxides: For colorants.

Key excipient suppliers are global companies specializing in pharmaceutical excipients. Some prominent examples include:

Ashland: A major supplier of cellulose derivatives and other functional excipients.
BASF SE: Offers a wide range of excipients, including methacrylic acid copolymers (Eudragit®).
Colorcon Inc.: Specializes in formulated film coatings and excipients.
Roquette Frères: A leading producer of plant-based ingredients, including starch derivatives and cellulose.
Evonik Industries AG: Known for its methacrylic acid-based polymers (Eudragit®).
Kerry Group: Provides functional excipients and ingredient solutions.
JRS Pharma (J. Rettenmaier & Söhne): Offers cellulose-based excipients.

The selection of excipients and their suppliers is critical for achieving the desired pharmacokinetic profile of dexlansoprazole and meeting regulatory requirements for drug product quality and stability.

What is the Regulatory Landscape for Dexlansoprazole Manufacturing?

The manufacturing of dexlansoprazole API and its finished dosage forms is subject to stringent regulatory oversight by health authorities worldwide. Key regulatory considerations include:

Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. GMP ensures that products are consistently produced and controlled according to quality standards.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and controls for the API. Finished dosage form manufacturers can reference these DMFs in their drug applications.
Site Inspections: Manufacturing sites for both API and finished products are subject to regular inspections by regulatory authorities to ensure ongoing compliance with GMP.
ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide harmonized standards for quality, safety, and efficacy, which are adopted by many regulatory agencies. This includes guidelines on impurity control (ICH Q3A/B/C), stability testing (ICH Q1A-F), and process validation (ICH Q7 for APIs).
Impurity Profiling: Manufacturers must rigorously identify, quantify, and control impurities in both the API and the finished drug product. Regulatory agencies set strict limits for genotoxic and other impurities.
Drug Product Registration: Manufacturers of finished dexlansoprazole products must obtain marketing authorization from relevant health authorities by submitting New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for generics, which include detailed information on manufacturing processes, quality control, and stability data.

Compliance with these regulations is non-negotiable and requires significant investment in quality systems, documentation, and personnel training.

What are the Supply Chain Risks and Mitigation Strategies?

The dexlansoprazole supply chain, like that of many pharmaceuticals, faces several potential risks:

Geopolitical Instability: Reliance on specific regions for API or intermediate manufacturing can expose the supply chain to disruptions from political events, trade disputes, or natural disasters.
Raw Material Shortages: Fluctuations in the availability or price of key starting materials or reagents can impact production costs and lead times.
Quality Control Failures: A single instance of failing to meet quality standards by a supplier can lead to batch rejection, recalls, and significant reputational damage.
Intellectual Property (IP) Disputes: For branded dexlansoprazole, ongoing IP protection is critical. Generic entry is heavily dependent on patent expiry and litigation outcomes.
Regulatory Changes: Evolving regulatory requirements or unexpected enforcement actions can necessitate costly process modifications or impact market access.
Logistical Challenges: Transportation delays, customs issues, or a lack of adequate cold chain logistics (if applicable for certain intermediates or stability requirements) can disrupt timely delivery.

Mitigation Strategies:

Supplier Diversification: Qualifying and maintaining relationships with multiple suppliers for critical raw materials, intermediates, and excipients can reduce reliance on a single source.
Dual Sourcing: For highly critical components, establishing agreements with two qualified suppliers concurrently provides a backup in case of primary supplier issues.
Robust Quality Agreements: Implementing comprehensive quality agreements with all suppliers, clearly defining specifications, testing requirements, change control procedures, and audit rights, is essential.
Inventory Management: Maintaining strategic safety stock of critical raw materials and finished goods, balanced against shelf-life and storage costs, can buffer against short-term disruptions.
Supplier Audits and Performance Monitoring: Conducting regular audits of supplier facilities and continuously monitoring their performance against agreed-upon metrics ensures ongoing compliance and quality.
Supply Chain Visibility: Investing in technologies and processes that enhance visibility across the entire supply chain, from raw material origins to finished product distribution, allows for proactive identification and management of potential risks.
Contingency Planning: Developing detailed contingency plans for various disruption scenarios, including alternative supplier activation and emergency production protocols.
Geographic Risk Assessment: Diversifying manufacturing locations or sourcing strategies to mitigate risks associated with specific geopolitical regions.

Key Takeaways

The dexlansoprazole API market is dominated by Takeda Pharmaceutical Company for the branded product and by major generic API manufacturers in India and China.
Critical intermediates such as 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine hydrochloride and sulfur-containing benzimidazole derivatives are key components sourced from specialized chemical synthesis firms.
Excipient suppliers, particularly those providing methacrylic acid copolymers (e.g., Eudragit®), are vital for the drug's dual-delayed release formulation.
Manufacturing operations are subject to strict GMP regulations, requiring comprehensive quality systems and regulatory filings (e.g., DMFs).
Supply chain risks include geopolitical instability, raw material shortages, quality control failures, and logistical challenges.
Effective mitigation strategies involve supplier diversification, dual sourcing, robust quality agreements, inventory management, and enhanced supply chain visibility.

Frequently Asked Questions

What is the typical lead time for sourcing a critical dexlansoprasole intermediate from a specialized chemical manufacturer? Lead times can range from 8 to 24 weeks, depending on the complexity of the synthesis, the supplier's existing production schedule, and the required scale of production. Custom synthesis projects may incur longer lead times.
How does the dual-delayed release mechanism of dexlansoprazole impact excipient selection and sourcing? The dual-delayed release relies on pH-sensitive polymers, primarily methacrylic acid copolymers. Sourcing these specialized excipients from manufacturers with established expertise and consistent batch-to-batch quality is critical. Companies like Evonik (Eudragit®) and BASF are key players in this niche.
Are there any specific regulatory hurdles for generic dexlansoprazole API manufacturers compared to the originator? Generic API manufacturers must demonstrate bioequivalence of their API and prove that their manufacturing process does not infringe on any existing patents. They also need to file complete Drug Master Files (DMFs) and pass rigorous FDA/EMA inspections, similar to the originator, but often under greater scrutiny regarding process control and impurity profiles compared to the innovator's initial filing.
What are the common impurity types associated with dexlansoprazole synthesis? Common impurities can include unreacted starting materials, synthesis by-products (e.g., related benzimidazoles or pyridines), oxidation products, and degradation products formed during storage. Specific examples might include sulfide precursors or over-oxidized sulfone forms.
In what ways do geopolitical tensions or trade policies impact the supply of dexlansoprazole raw materials? Geopolitical tensions or restrictive trade policies can lead to increased tariffs, export/import restrictions, or even complete cessation of trade for certain chemicals originating from affected regions. This can disrupt the supply of essential raw materials and intermediates, driving up costs and potentially causing shortages, forcing companies to re-evaluate sourcing strategies and seek alternative suppliers in more stable regions.

Cited Sources

[1] U.S. Food & Drug Administration. (n.d.). Good Manufacturing Practice (GMP) Resources. Retrieved from [FDA GMP Website] (Note: A specific URL would be provided if available, but for general GMP principles, this is representative.)

[2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA GMP Website] (Note: Similar to FDA, a specific URL would be used if citing a direct guideline.)

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guidelines. Retrieved from [ICH Website] (Note: Specific ICH guideline numbers like Q7, Q3A, Q1A would be cited if directly referencing their content.)

[4] Takeda Pharmaceutical Company Limited. (Various Years). Annual Reports and Investor Relations Information. (Note: Specific report years and relevant pages would be cited if data were directly extracted.)

[5] Market research reports on the global PPI market and dexlansoprazole. (Note: Specific reports from firms like IQVIA, GlobalData, Grand View Research would be cited if data points were directly taken from them. Generic mention here acknowledges the source of market data trends.)

Suppliers and packagers for generic pharmaceutical drug: dexlansoprazole